About Ikaria
Ikaria is a Healthcare company based in Hampton (United States) founded in 2005, and was acquired by Mallinckrodt Pharmaceuticals in March 2015. Therapies for respiratory-related cardiopulmonary disorders are developed. Ikaria has raised $434.92 million across 6 funding rounds from investors including Mallinckrodt Pharmaceuticals, Arch Venture Partners and 5AM Ventures. The company has 429 employees. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its competitors include aTyr Pharma, ReCode Therapeutics and InterMune; 2 of its 3 listed competitors have raised funding.
Company details
Ikaria was founded in 2005 and is headquartered in Hampton, United States. Focus is placed on developing therapies for respiratory-related cardiopulmonary disorders within the biotechnology sector. INOtherapy is provided, incorporating INOMAX (nitric oxide) for inhalation, which has received FDA approval for hypoxic respiratory failure. Late-stage trials are ongoing for bronchopulmonary dysplasia and acute respiratory distress syndrome. Pipeline efforts address hepatorenal syndrome, heart failure, tissue ischemia, and vascular leakage.
- Headquarters Hampton, United States
- Employees 429
- Stage Acquired
- SectorsHealthcare
- Website ikaria.com
- Social LinkedIn
- Acquired by Mallinckrodt Pharmaceuticals (Mar 2015)
- Total Equity Funding$434.92M (USD)
in 6 rounds
- Latest Funding Round$850M (USD), Debt – Conventional
Jul 2013
- InvestorsMallinckrodt Pharmaceuticals
& 6 more
- Employee Count429
- Acquired by
Funding Insights of Ikaria
Ikaria has successfully raised a total of $434.92M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $850 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $434.92M
- Total Rounds 6
- Last Round Debt – Conventional — $850M
- First Round $10M
(Apr 2005)
- Investors Count 5
All 6 funding rounds of Ikaria with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2013 | $850M | Debt – Conventional | – | – | – |
| Oct 2009 | $54.95M | Series C | – | – | – |
| Oct 2008 | $154,601 | Series C | – | – | – |
| Jul 2008 | $8.04M | Series C | – | – | – |
| Apr 2007 | $361.78M | Series C | – | – | – |
| Apr 2005 | $10M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Ikaria
Ikaria has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, Arch Venture Partners and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Early-stage venture capital is provided to US companies across sectors. | wrfseattle.org | Seattle, United States | ||
Growth capital is provided by Aravis for Swiss high-tech companies. | aravis.ch | Switzerland | ||
Private equity investments are directed toward key sectors by MDP. | mdcp.com | Chicago, United States | ||
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for Ikaria
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ikaria
5 dated milestones of Ikaria across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Ikaria is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Debt – Conventional, of $850.0M.
- Exit Acquired by MDP.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
Competitors of Ikaria
Ikaria has 3 listed competitors in our database, 2 of them funded. They include aTyr Pharma, ReCode Therapeutics and InterMune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | Precision medicines for lung-related diseases are developed. | ||
| intermune.com | 1998 | Brisbane, United States | 359 | Therapies in pulmonology and orphan fibrotic diseases. |
Detailed competitors of Ikaria
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ikaria
Websites that share an audience with Ikaria (ikaria.com).
Websites whose visitors overlap most with Ikaria. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
absolutelyabby.com | absolutelyabby.com | 100% | – | ||
| reuters.com | 96% | 96.5M | #881 | View details | |
| bloomberg.com | 69% | 51.1M | #1,495 | View details |
Top companies in Pulmonology
3 companies that operate in the same segment as Ikaria (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ikaria
Complete news archive for Ikaria
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ikaria
Ikaria was founded in 2005.
Ikaria is headquartered in Hampton, United States. It is registered at Hampton, Virginia, United States.
Ikaria is a funded company, having raised a total of $434.92M across 6 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Apr 2005.
Ikaria has 429 employees.
Ikaria was founded in 2005 and is headquartered in Hampton, United States. Focus is placed on developing therapies for respiratory-related cardiopulmonary disorders within the biotechnology sector. INOtherapy is provided, incorporating INOMAX (nitric oxide) for inhalation, which has received FDA approval for hypoxic respiratory failure. Late-stage trials are ongoing for bronchopulmonary dysplasia and acute respiratory distress syndrome. Pipeline efforts address hepatorenal syndrome, heart failure, tissue ischemia, and vascular leakage.
Ikaria's top competitors include aTyr Pharma, ReCode Therapeutics and InterMune.
Ikaria has 7 investors. Key investors include Mallinckrodt Pharmaceuticals, Arch Venture Partners, 5AM Ventures, Venrock, and Washington Research Foundation.
Yes. Ikaria was acquired by Mallinckrodt Pharmaceuticals in March 2015.